Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Summary
Sponsor is doing this research to find out if an experimental medication, benralizumab, will work and be safe for the treatment of EGPA. To see if benralizumab has an impact in treating EGPA, this study will compare it with an active comparator, mepolizumab, that has regulatory approval in several markets for use in patients with EGPA.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 80
Inclusion criteria:
You might be eligible to participate in this trial if:
1) you are 18 years of age and older
2) you have EGPA.
Exclusion criteria:
You might not be eligible to participate in this trial if:
1) you do not have EGPA
2) you are pregnant
3) you are under the age of 18.
Participate
Additional information
Contact information
If you would like to learn more about how you can get involved with this trial, please contact our study coordinator, Linda, at 403-220-8680.
Principal investigator:
Brandie Walker
Clinical trial:
Yes
REB-ID:
REB19-1821